We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Dynavax Gets FDA Green Light to Resume Its Heplisav Study
Dynavax Gets FDA Green Light to Resume Its Heplisav Study
September 16, 2009
Dynavax Technologies will resume a Phase III study of its hepatitis B vaccine Heplisav soon because the FDA has lifted an 18-month clinical hold on testing in patients with chronic kidney disease.